Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05089461 Not yet recruiting - Clinical trials for Advanced Malignant Tumor

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Start date: October 30, 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, phase II study to evaluate the cardiac safety of Mitoxantrone Hydrochloride Liposome in patients with advanced malignant tumor who has received at least first-line treatment.

NCT ID: NCT05088356 Recruiting - Clinical trials for Myelodysplastic Syndromes

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Start date: September 7, 2021
Phase: Phase 1
Study type: Interventional

Reduced intensity conditioning (RIC) has been increasingly adopted as a modality to allow preparative conditioning pre-transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study Reduced intensity conditioning (RIC) conditioning is used and followed by match aploidentical donor peripheral blood stem cell transplantation.

NCT ID: NCT05088070 Recruiting - Solid Tumor Clinical Trials

Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors

Start date: July 10, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1 clinical trial of SPH3348 tablets, a c-Met inhibitor, in patients with advanced solid tumors with c-Met abnormalities. A modified 3 + 3 design was adopted in patients with advanced solid tumors with c-Met abnormalities, with a total of 6 dose groups, in which accelerated dose escalation was adopted for the lowest dose group, and 3 + 3 dose escalation was adopted from the second dose group. The primary objective was to evaluate the safety and tolerability of SPH3348 tablets in patients with advanced solid tumors with c-Met abnormalities.

NCT ID: NCT05087745 Recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

Start date: December 10, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.

NCT ID: NCT05086848 Completed - Clinical trials for Advanced Solid Tumors

A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors

Start date: May 5, 2016
Phase: Phase 1
Study type: Interventional

This is a dose-escalation and expansion, open label, single centre, phase Ib study. In this study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride liposome injection in combination with 5-FU/LV were studied in patients with advanced solid tumors. Meanwhile, to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan hydrochloride liposome.

NCT ID: NCT05086822 Completed - Clinical trials for Advanced Solid Tumors

A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors

Start date: September 9, 2014
Phase: Phase 1
Study type: Interventional

This is an open label, dose-escalation and expansion, single centre, phase Ia study . In this study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride liposome injection were studied in patients with advanced solid tumors, to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan hydrochloride liposome.

NCT ID: NCT05086692 Recruiting - Colorectal Cancer Clinical Trials

A Beta-only IL-2 ImmunoTherapY (ABILITY) Study

Start date: August 27, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

NCT ID: NCT05085548 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

Start date: November 2021
Phase: Phase 1
Study type: Interventional

The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.

NCT ID: NCT05084027 Recruiting - Clinical trials for Hematologic Malignancy

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Hematologic Malignancies

Start date: October 7, 2021
Phase: Phase 2
Study type: Interventional

venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies

NCT ID: NCT05083481 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of ASP1570 in Adults With Advanced Solid Tumors

Start date: October 31, 2021
Phase: Phase 1
Study type: Interventional

This study is for adults with advanced solid tumors. Their tumor has either grown outside of the area where it started or it has spread to other parts of the body. Their cancer gets worse after standard therapy or they are unable to have standard therapy. This study will provide more information on a potential new treatment for people with advanced solid tumors, called ASP1570. This study will be in 2 parts. In Part 1, the best dose of ASP1570 to give to people with advanced solid tumors will be worked out. Different small groups of people with advanced solid tumors will take lower to higher doses of ASP1570. There are 8 different doses in total, with each group staying on the same dose. After taking the lowest dose, the first group will be checked for medical problems. The next group can only take the higher dose if the first group on the lowest dose had no major medical problems. This will continue in the same way for each group. This means each group will take the next highest dose of ASP1570 as long as the previous group did not have any major medical problems. Each group will take tablets of ASP1570 either once or twice every day in a 21-day cycle. They will continue with more treatment cycles on the same dose unless they have major medical problems, their cancer gets worse or the study doctor decides that person should stop treatment. In Part 2, different small groups of people with advanced solid tumors will take the best dose of ASP1570 worked out from Part 1. The dose will not go above the highest dose that people took in Part 1 without getting major medical problems. Some groups of people will have specific advanced tumors. These include tumors from metastatic melanoma or non-small cell lung cancer (NSCLC for short). Other groups will have solid tumors that showed a response in Part 1. Again, each group will take tablets of ASP1570 once every day in a 21-day cycle. They will continue with more treatment cycles unless they have major medical problems, their cancer gets worse or the study doctor decides that person should stop treatment. After treatment, people in the study will visit their clinic 45 days after their last dose of ASP1570. Then, the study clinic will contact each person in the study at least every 12 weeks until the end of the study or if they decide to leave the study.